Robert A Wood1, Jennifer S Kim2, Robert Lindblad3, Kari Nadeau4, Alice K Henning3, Peter Dawson3, Marshall Plaut5, Hugh A Sampson6. 1. Johns Hopkins University School of Medicine, Baltimore, Md. 2. NorthShore University HealthSystem, Evanston, Ill. 3. EMMES Corporation, Rockville, Md. 4. Stanford University School of Medicine, Stanford, Calif. 5. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 6. Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: hugh.sampson@mssm.edu.
Abstract
BACKGROUND: Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued. OBJECTIVE: We sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both. METHODS: This was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU). RESULTS:Fifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g "desensitization" OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008). CONCLUSIONS: In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU).
RCT Entities:
BACKGROUND: Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued. OBJECTIVE: We sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both. METHODS: This was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU). RESULTS: Fifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g "desensitization" OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008). CONCLUSIONS: In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU).
Authors: Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale Journal: J Allergy Clin Immunol Date: 2003-12 Impact factor: 10.793
Authors: Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2011-11-30 Impact factor: 10.793
Authors: Hugh A Sampson; Donald Y M Leung; A Wesley Burks; Gideon Lack; Sami L Bahna; Stacie M Jones; Dennis A Wong Journal: J Allergy Clin Immunol Date: 2011-03-11 Impact factor: 10.793
Authors: R J van Neerven; C P van Roomen; W R Thomas; M de Boer; E F Knol; F M Davis Journal: Int Arch Allergy Immunol Date: 2001 Jan-Mar Impact factor: 2.749
Authors: Satya D Narisety; Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Mark Gorelik; John Schroeder; Robert G Hamilton; Robert A Wood Journal: J Allergy Clin Immunol Date: 2014-12-18 Impact factor: 10.793
Authors: Joshua A Boyce; Amal Assa'ad; A Wesley Burks; Stacie M Jones; Hugh A Sampson; Robert A Wood; Marshall Plaut; Susan F Cooper; Matthew J Fenton; S Hasan Arshad; Sami L Bahna; Lisa A Beck; Carol Byrd-Bredbenner; Carlos A Camargo; Lawrence Eichenfield; Glenn T Furuta; Jon M Hanifin; Carol Jones; Monica Kraft; Bruce D Levy; Phil Lieberman; Stefano Luccioli; Kathleen M McCall; Lynda C Schneider; Ronald A Simon; F Estelle R Simons; Stephen J Teach; Barbara P Yawn; Julie M Schwaninger Journal: J Allergy Clin Immunol Date: 2010-12 Impact factor: 10.793
Authors: Marc Massanari; Harold Nelson; Thomas Casale; William Busse; Farid Kianifard; Gregory P Geba; Robert K Zeldin Journal: J Allergy Clin Immunol Date: 2010-02 Impact factor: 10.793
Authors: Justin M Skripak; Scott D Nash; Hannah Rowley; Nga H Brereton; Susan Oh; Robert G Hamilton; Elizabeth C Matsui; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2008-10-25 Impact factor: 10.793
Authors: François Graham; Natacha Tardio; Louis Paradis; Anne Des Roches; Philippe Bégin Journal: Hum Vaccin Immunother Date: 2017-10-03 Impact factor: 3.452
Authors: Caitlin M Burk; Evan S Dellon; Pamela H Steele; Yamini V Virkud; Mike Kulis; A Wesley Burks; Brian P Vickery Journal: J Allergy Clin Immunol Pract Date: 2016-12-22